Long-term studies of dopamine agonists

Neurology
Jean Hubble

Abstract

Dopamine agonists have long been used as adjunctive therapy for the treatment of Parkinson's disease (PD). In more recent years these drugs have also been proved safe and effective as initial therapy in lieu of levodopa in the treatment of PD. Long-term levodopa therapy is associated with motor complications, including fluctuating response patterns and dyskinesia. By initially introducing a dopamine agonist as symptomatic drug therapy, it may be possible to postpone the use of levodopa and delay or prevent the development of motor complications. Recently, four clinical trials have explored this hypothesis by comparing the long-term response and side effects of levodopa with dopamine agonist therapy. The drugs studied have included ropinirole, pramipexole, cabergoline, and pergolide. In each of these projects, the occurrence of motor complications, such as wearing off and dyskinesia, was significantly less in the subjects assigned to initiation of therapy with a dopamine agonist. The addition of levodopa could be postponed by many months or even several years. Therefore, these long-term studies of dopamine agonists support the initiation of a dopamine agonist instead of levodopa in an effort to postpone levodopa-related motor co...Continue Reading

Citations

Jan 9, 2003·Lancet·Jagdish SharmaDavid Stewart
Aug 22, 2008·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J C MöllerW H Oertel
Jan 10, 2012·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·O Gershanik, P Jenner
Oct 16, 2004·Cephalalgia : an International Journal of Headache·J KlapperUNKNOWN ZODIAC study group
Oct 16, 2004·Cephalalgia : an International Journal of Headache·J ScholppN Banik
Aug 2, 2002·Current Opinion in Neurology·Ron Tintner, Joseph Jankovic
Jun 7, 2013·Expert Review of Neurotherapeutics·Brenton A Wright, Cheryl H Waters
Aug 24, 2006·Expert Opinion on Pharmacotherapy·Thomas Müller, Hermann Russ
Dec 10, 2015·Expert Opinion on Drug Safety·Roberto CeravoloUbaldo Bonuccelli
Dec 10, 2013·Expert Opinion on Investigational Drugs·Fabio Blandini, Marie-Therese Armentero
Jul 5, 2011·Neurología : publicación oficial de la Sociedad Española de Neurología·A Alonso CánovasJ C Martínez Castrillo
Sep 25, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Katherine GrossetDonald Grosset
Apr 10, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Kazuo YamashiroYoshikuni Mizuno
Apr 14, 2011·British Journal of Pharmacology·Susan Duty, Peter Jenner
Jan 29, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Kayhan A Tayarani-BinazirPeter Jenner
Aug 1, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Esteve Brugue, Eduard Vieta
Jun 29, 2004·Biological Psychiatry·Carlos A ZarateHusseini K Manji
Jul 26, 2015·Progress in Neurobiology·Matthieu F BastideErwan Bézard
Aug 26, 2016·Expert Opinion on Pharmacotherapy·Fabrizio StocchiChiara Fossati
Feb 4, 2003·Nature Reviews. Neuroscience·Sultan DarveshChangiz Geula
Nov 4, 2015·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·N V Titova
Apr 3, 2019·Drugs & Aging·Martin KlietzGünter U Höglinger

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.